483
F. Hoffmann-La Roche AGF. Hoffmann-La Roche AG – FDA 483
Record Details
An FDA inspection of F. Hoffmann-La Roche Ltd.'s drug substance manufacturing facility in Basel, Switzerland, identified an inadequate monitoring frequency for water used in manufacturing. Specifically, the water used directly in the process stream was not sampled frequently enough for bioburden and endotoxin at its points of use. This indicates a potential quality control issue in the manufacturing process.
- Company
- F. Hoffmann-La Roche AG
- Product type
- drugs
View Company Profile
ID · ea1d5604-e9fe-453a-9201-d1168dfc97a2
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.